Taselisib, a selective inhibitor of PIK3CA, is highly effective on PIK3CA-mutated and HER2/neu amplified uterine serous carcinoma in vitro and in vivo

Gynecologic Oncology

Volumn 135, Issue 2, 2014, Pages 312-317

  Lopez, Salvatore ^a   Schwab, Carlton L ^b   Cocco, Emiliano ^b   Bellone, Stefania ^b   Bonazzoli, Elena ^b   English, Diana P ^b   Schwartz, Peter E ^b   Rutherford, Thomas ^b   Angioli, Roberto ^a   Santin, Alessandro D ^b  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

GDC 0032; HER2 neu; PIK3CA mutation; PIK3CA mutant mouse; Taselisib; Uterine serous tumors

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; PROTEIN S6; TASELISIB; 2-(3-(2-(1-ISOPROPYL-3-METHYL-1H-1,2-4-TRIAZOL-5-YL)-5,6-DIHYDROBENZO(F)IMIDAZO(1,2-D)(1,4)OXAZEPIN-9-YL)-1H-PYRAZOL-1-YL)-2-METHYLPROPANAMIDE; ANTINEOPLASTIC AGENT; ERBB2 PROTEIN, HUMAN; IMIDAZOLE DERIVATIVE; OXAZEPINE DERIVATIVE; PHOSPHATIDYLINOSITOL 3 KINASE; PIK3CA PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASSAY; CANCER SURVIVAL; CARCINOMA CELL LINE; CELL CYCLE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CONTROLLED STUDY; DNA CONTENT; EXPERIMENTAL MODEL; FEMALE; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MUTATION; NONHUMAN; PROTEIN PHOSPHORYLATION; TUMOR GROWTH; UTERINE SEROUS CARCINOMA; UTERINE SEROUS CARCINOMA CELL LINE; UTERUS CARCINOMA; WILD TYPE; XENOGRAFT; ADULT; AGED; ANIMAL; ANTAGONISTS AND INHIBITORS; CARCINOMA; CELL CYCLE CHECKPOINT; CELL PROLIFERATION; DRUG EFFECTS; DRUG SCREENING; GENETICS; MIDDLE AGED; NEOPLASM; TUMOR CELL LINE; UTERUS CANCER; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; GENE AMPLIFICATION; HUMANS; IMIDAZOLES; IN SITU HYBRIDIZATION, FLUORESCENCE; IN VITRO TECHNIQUES; MICE; MIDDLE AGED; NEOPLASMS, CYSTIC, MUCINOUS, AND SEROUS; OXAZEPINES; PHOSPHATIDYLINOSITOL 3-KINASES; RECEPTOR, ERBB-2; UTERINE NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84914158009     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2014.08.024     Document Type: Article

References (46)

1. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics, 2013 CA Cancer J Clin 63 2013 11 30
2. J.V. Bokhman Two pathogenetic types of endometrial carcinoma Gynecol Oncol 15 1983 10 17
3. M. Hendrickson, J. Ross, P. Eifel, A. Martinez, and R. Kempson Uterine papillary serous carcinoma: a highly malignant form of endometrial adenocarcinoma Am J Surg Pathol 6 1982 93 108
4. C.A. Hamilton, M.K. Cheung, K. Osann, L. Chen, N.N. Teng, and T.A. Longacre Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers Br J Cancer 94 2006 642 646
5. D.M. Boruta II, P.A. Gehrig, P.A. Groben, V. Bae-Jump, J.F. Boggess, and W.C. Fowler Jr. Uterine serous and grade 3 endometrioid carcinomas: is there a survival difference? Cancer 101 2004 2214 2221
6. R.E. Bristow, F. Asrari, E.L. Trimble, and F.J. Montz Extended surgical staging for uterine papillary serous carcinoma: survival outcome of locoregional (stage I-III) disease Gynecol Oncol 81 2001 279 286
7. F.D. Cirisano Jr., S.J. Robboy, R.K. Dodge, R.C. Bentley, H.R. Krigman, and I.S. Synan Epidemiologic and surgicopathologic findings of papillary serous and clear cell endometrial cancers when compared to endometrioid carcinoma Gynecol Oncol 74 1999 385 394
8. J.L. Nicklin, and L.J. Copeland Endometrial papillary serous carcinoma: patterns of spread and treatment Clin Obstet Gynecol 39 1996 686 695
9. Y. Samuels, Z. Wang, A. Bardelli, N. Silliman, J. Ptak, and S. Szabo High frequency of mutations of the PIK3CA gene in human cancers Science 304 2004 554
10. Y. Kanamori, J. Kigawa, H. Itamochi, M. Shimada, M. Takahashi, and S. Kamazawa Correlation between loss of PTEN expression and Akt phosphorylation in endometrial carcinoma Clin Cancer Res 7 2001 892 895
11. K. Oda, D. Stokoe, Y. Taketani, and F. McCormick High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma Cancer Res 65 2005 10669 10673
12. K.J. Dedes, D. Wetterskog, A. Ashworth, S.B. Kaye, and J.S. Reis-Filho Emerging therapeutic targets in endometrial cancer Nat Rev Clin Oncol 8 2011 261 271
13. H.B. Salvesen, S.L. Carter, M. Mannelqvist, A. Dutt, G. Getz, and I.M. Stefansson Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation Proc Natl Acad Sci U S A 106 2009 4834 4839
14. B.M. Slomovitz, and R.L. Coleman The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer Clin Cancer Res 18 2012 5856 5864
15. A.P. Myers New strategies in endometrial cancer: targeting the PI3K/mTOR pathway - the devil is in the details Clin Cancer Res 19 2013 5264 5274
16. D.P. English, D.M. Roque, and A.D. Santin HER2 expression beyond breast cancer: therapeutic implications for gynecologic malignancies Mol Diagn Ther 17 2013 85 99
17. N. Buza, D.P. English, A.D. Santin, and P. Hui Toward standard HER2 testing of endometrial serous carcinoma: 4-year experience at a large academic center and recommendations for clinical practice Mod Pathol 26 2013 1605 1612
18. S. Zhao, M. Choi, J.D. Overton, S. Bellone, D.M. Roque, and E. Cocco Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma Proc Natl Acad Sci U S A 110 2013 2916 2921
19. Q.B. She, S. Chandarlapaty, Q. Ye, J. Lobo, K.M. Haskell, and K.R. Leander Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling PLoS One 3 2008 e3065
20. D.P. English, S. Bellone, E. Cocco, I. Bortolomai, S. Pecorelli, and S. Lopez Oncogenic PIK3CA gene mutations and HER2/neu gene amplifications determine the sensitivity of uterine serous carcinoma cell lines to GDC-0980, a selective inhibitor of Class I PI3 kinase and mTOR kinase (TORC1/2) Am J Obstet Gynecol 209 465 2013 e1 e9
21. C.O. Ndubaku, T.P. Heffron, S.T. Staben, M. Baumgardner, N. Blaquiere, and E. Bradley Discovery of 2-{3-[2-(1-isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl]-1H-pyrazol-1-yl}-2-methylpropanamide (GDC-0032): a beta-sparing phosphoinositide 3-kinase inhibitor with high unbound exposure and robust in vivo antitumor activity J Med Chem 56 2013 4597 4610
22. C. Fritsch, A. Huang, C. Chatenay-Rivauday, C. Schnell, A. Reddy, and M. Liu Characterization of the novel and specific PI3Kalpha inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials Mol Cancer Ther 13 2014 1117 1129
23. A. Puissant, S.M. Frumm, G. Alexe, C.F. Bassil, J. Qi, and Y.H. Chanthery Targeting MYCN in neuroblastoma by BET bromodomain inhibition Cancer Discov 3 2013 308 323
24. Cancer Genome Atlas Research N, C. Kandoth, N. Schultz, A.D. Cherniack, R. Akbani, and Y. Liu Integrated genomic characterization of endometrial carcinoma Nature 497 2013 67 73
25. M. Le Gallo, A.J. O'Hara, M.L. Rudd, M.E. Urick, N.F. Hansen, and N.J. O'Neil Exome sequencing of serous endometrial tumors identifies recurrent somatic mutations in chromatin-remodeling and ubiquitin ligase complex genes Nat Genet 44 2012 1310 1315
26. E. Kuhn, R.C. Wu, B. Guan, G. Wu, J. Zhang, and Y. Wang Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses J Natl Cancer Inst 104 2012 1503 1513
27. J. Luo, B.D. Manning, and L.C. Cantley Targeting the PI3K-Akt pathway in human cancer: rationale and promise Cancer Cell 4 2003 257 262
28. A.D. Santin, S. Bellone, M. Gokden, M. Palmieri, D. Dunn, and J. Agha Overexpression of HER-2/neu in uterine serous papillary cancer Clin Cancer Res 8 2002 1271 1279
29. B.M. Slomovitz, R.R. Broaddus, T.W. Burke, N. Sneige, P.T. Soliman, and W. Wu Her-2/neu overexpression and amplification in uterine papillary serous carcinoma J Clin Oncol 22 2004 3126 3132
30. A.D. Santin, S. Bellone, S. Van Stedum, W. Bushen, L.E. De Las Casas, and S. Korourian Determination of HER2/neu status in uterine serous papillary carcinoma: comparative analysis of immunohistochemistry and fluorescence in situ hybridization Gynecol Oncol 98 2005 24 30
31. C. Morrison, V. Zanagnolo, N. Ramirez, D.E. Cohn, N. Kelbick, and L. Copeland HER-2 is an independent prognostic factor in endometrial cancer: association with outcome in a large cohort of surgically staged patients J Clin Oncol 24 2006 2376 2385
32. T.P. Diaz-Montes, H. Ji, A.E. Smith Sehdev, M.L. Zahurak, R.J. Kurman, and D.K. Armstrong Clinical significance of Her-2/neu overexpression in uterine serous carcinoma Gynecol Oncol 100 2006 139 144
33. M.P. Hayes, W. Douglas, and L.H. Ellenson Molecular alterations of EGFR and PIK3CA in uterine serous carcinoma Gynecol Oncol 113 2009 370 373
34. M.L. Rudd, J.C. Price, S. Fogoros, A.K. Godwin, D.C. Sgroi, and M.J. Merino A unique spectrum of somatic PIK3CA (p110alpha) mutations within primary endometrial carcinomas Clin Cancer Res 17 2011 1331 1340
35. M.K. McConechy, J. Ding, M.C. Cheang, K.C. Wiegand, J. Senz, and A.A. Tone Use of mutation profiles to refine the classification of endometrial carcinomas J Pathol 228 2012 20 30
36. S. Kang, A.G. Bader, and P.K. Vogt Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic Proc Natl Acad Sci U S A 102 2005 802 807
37. I.G. Campbell, S.E. Russell, D.Y. Choong, K.G. Montgomery, M.L. Ciavarella, and C.S. Hooi Mutation of the PIK3CA gene in ovarian and breast cancer Cancer Res 64 2004 7678 7681
38. M. Cully, H. You, A.J. Levine, and T.W. Mak Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis Nat Rev Cancer 6 2006 184 192
39. D.A. Fruman, and C. Rommel PI3K and cancer: lessons, challenges and opportunities Nat Rev Drug Discov 13 2014 140 156
40. J. Rodon, R. Dienstmann, V. Serra, and J. Tabernero Development of PI3K inhibitors: lessons learned from early clinical trials Nat Rev Clin Oncol 10 2013 143 153
41. K.D. Courtney, R.B. Corcoran, and J.A. Engelman The PI3K pathway as drug target in human cancer J Clin Oncol 28 2010 1075 1083
42. A.R. Gottschalk, D. Basila, M. Wong, N.M. Dean, C.H. Brandts, and D. Stokoe p27Kip1 is required for PTEN-induced G1 growth arrest Cancer Res 61 2001 2105 2111
43. A. Pavlidou, and N.F. Vlahos Molecular alterations of PI3K/Akt/mTOR pathway: a therapeutic target in endometrial cancer ScientificWorldJournal 2014 2014 709736
44. J. LoPiccolo, G.M. Blumenthal, W.B. Bernstein, and P.A. Dennis Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations Drug Resist Updat 11 2008 32 50
45. J.T. Garrett, A. Chakrabarty, and C.L. Arteaga Will PI3K pathway inhibitors be effective as single agents in patients with cancer? Oncotarget 2 2011 1314 1321
46. J. Tan, and Q. Yu Molecular mechanisms of tumor resistance to PI3K-mTOR-targeted therapy Chin J Cancer 32 2013 376 379